Watching Sio Gene Therapies Inc. (SIOX) For Insider Activity

0
63

Sio Gene Therapies Inc. (NASDAQ:SIOX) traded with a subtraction of $0.0 to close at $0.44 on Friday, a downside of -0.95 percent. An average of 652,540 shares of common stock have been traded in the last five days. There was a fall of -$0.0039 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,421,860 shares traded, while the 50-day average volume stands at 717,412.

SIOX stock has increased by 43.67% in the last month. The company shares reached their 1-month lowest point of $0.2900 on 12/09/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.23 and a high of $1.52 in 52 weeks. It has reached a new high 1 time so far this year and lost -65.93% or -$0.8539 in price. In spite of this, the price is down -71.45% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Valuation Metrics

Sio Gene Therapies Inc. (SIOX) stock’s beta is 1.34. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.63.

Financial Health

The quick ratio of Sio Gene Therapies Inc. for the three months ended March 30 was 6.50, and the current ratio was 6.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at $27000.0 compared to revenue of $71.56 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Sio Gene Therapies Inc.’s return on assets was -84.20%.

Earnings Surprise

In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$3.08 million in the quarter, while revenues of -$8.41 million were shrunk -589.61%. The analyst consensus anticipated Sio Gene Therapies Inc.’s latest quarter earnings to come in at -$0.2 per share, but it turned out to be -$0.18, a 10.00% surprise. For the quarter, EBITDA amounted to -$3.41 million. Shareholders own equity worth $73.97 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Sio Gene Therapies Inc. (SIOX) price momentum. RSI 9-day as of the close on 29 December was 75.29%, suggesting the stock is Overbought, with historical volatility in this time frame at 22.79%.

As of today, SIOX’s price is $0.4380 -0.89% or -$0.0039 from its 5-day moving average. SIOX is currently trading +37.57% higher than its 20-day SMA and +30.92% higher than its 100-day SMA. However, the stock’s current price level is +45.37% above the SMA50 and -27.16% below the SMA200.

The stochastic %K and %D were 95.25% and 95.89%, respectively, and the average true range (ATR) was 0.0204. With the 14-day stochastic at 94.57% and the average true range at 0.0227, the RSI (14) stands at 74.11%. The stock has reached 0.0002 on the 9-day MACD Oscillator while the 14-day reading was at 0.0276.

LEAVE A REPLY

Please enter your comment!
Please enter your name here